Agueda Mercado
Internal Medicine · New York, NYNPI 1255360368
Payments from drug & device makers
Across 213 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$745
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$461
- E.r. Squibb & Sons, L.L.C.$450
- GSK$372
- Amgen$362
- AbbVie$346
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,957100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $745 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $461 |
| E.r. Squibb & Sons, L.L.C. | 24 | $450 |
| GSK | 25 | $372 |
| Amgen(2 entities) | 22 | $362 |
| AbbVie(2 entities) | 12 | $346 |
| Novartis | 11 | $211 |
| Bayer | 7 | $158 |
| Lilly USA, LLC | 6 | $116 |
| Merck | 5 | $98 |
| Kowa Pharmaceuticals America, Inc. | 4 | $74 |
| Shield Therapeutics Inc | 3 | $65 |
| Ardelyx, Inc. | 3 | $62 |
| Phathom Pharmaceuticals, Inc. | 3 | $55 |
| Astellas Pharma US Inc | 2 | $54 |
| Amarin Pharma, Inc. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Pfizer | 3 | $41 |
| Novo Nordisk | 2 | $39 |
| Exact Sciences | 1 | $27 |
| Boehringer Ingelheim | 1 | $26 |
| Mission Pharmacal Company | 1 | $22 |
| Althera Pharmaceuticals LLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
| VBI Vaccine (delaware) Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $14 |
How this compares
$3,957 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 237 | $264,902 |
| JanuviaSitagliptin Phosphate | 241 | $227,418 |
| JardianceEmpagliflozin | 128 | $164,362 |
| FarxigaDapagliflozin Propanediol | 134 | $156,419 |
| VascepaIcosapent Ethyl | 371 | $141,464 |
| TrulicityDulaglutide | 72 | $115,164 |
| LinzessLinaclotide | 160 | $112,155 |
| Breo ElliptaFluticasone/Vilanterol | 224 | $88,855 |
| EliquisApixaban | 62 | $74,196 |
| JanumetSitagliptin Phos/Metformin Hcl | 69 | $62,352 |
| EntrestoSacubitril/Valsartan | 53 | $58,577 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 93 | $57,426 |
| RybelsusSemaglutide | 21 | $31,236 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 739 | $23,267 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 66 | $23,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $98 | $307,743339 claims |
| Novo NordiskOzempic, Rybelsus | $39 | $296,138258 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $745 | $228,741299 claims |
| Boehringer IngelheimJardiance, Tradjenta | $26 | $185,918143 claims |
| AbbVieLinzess, Restasis | $346 | $125,262174 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $372 | $124,744292 claims |
| Lilly USA, LLCTrulicity | $116 | $115,16472 claims |
| PfizerEliquis, Lyrica | $41 | $80,50574 claims |
| NovartisEntresto | $211 | $58,57753 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant | $49 | $15,18033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.